Skip links

Brexit-proofing EMDA® Patients

Following the recommendation in January 2019 by NICE  to use EMDA® in research programmes as a treatment for bladder cancer, JS Medical has taken steps to ensure there will be no change to our delivery schedules in coming months.

Whilst it is difficult to predict the course of Brexit and its affect on the supply of medical products, we have made a substantial investment in stock to reassure our client hospitals that EMDA® consumables will continue to be delivered as normal within 48 hours of ordering.

The NICE* guidance recommends that EMDA® should be used as part of research studies treating Non-Muscular Invasive Bladder Cancer. There are currently studies underway at several Urology clinics including Guy’s & St Thomas’ NHS Foundation Trust in London and Salisbury District Hospital, where the Urology team have experienced extremely positive results for patients participating in the research.

If you would like to introduce an EMDA® study as part of your bladder cancer treatment programme, find out how JS Medical can help your team by calling Robin Luper on 01234-888955 or sending an email to info@js-group.global

 

Further information

EMDA® Treatment

Salisbury District Hospital

*NICE (National Institute for Health and Clinical Excellence)

NHS England Bladder Cancer